FDA Approves ABREVA — Haleon US Holdings LLC

# FDA Approves Haleon's ABREVA (Docosanol) for Cold Sore Treatment Haleon US Holdings LLC has received FDA approval for ABREVA (docosanol), a topical antiviral treatment for cold sores, marking the first non-prescription option to reduce healing time and potentially opening a significant market opportunity in the over-the-counter cold sore segment. The approval positions Haleon to capture share in the estimated multi-hundred-million-dollar consumer cold sore care market, where the company can leverage its consumer health distribution network to achieve rapid market penetration